Have a feature idea you'd love to see implemented?
Let us know!
OTLK Outlook Therapeutics Inc
Price (delayed)
$2.16
Market cap
$53.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.06
Enterprise value
$68.61M
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME
Highlights
The EPS has grown by 49% from the previous quarter and by 14% YoY
OTLK's debt is down by 16% year-on-year and by 9% since the previous quarter
The net income has contracted by 28% YoY but it has grown by 20% from the previous quarter
The quick ratio has dropped by 53% since the previous quarter and by 30% year-on-year
Key stats
What are the main financial stats of OTLK
Market
Valuations
Earnings
Shares outstanding
24.91M
Market cap
$53.8M
Enterprise value
$68.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$75.37M
EBIT
-$72.21M
EBITDA
-$72.09M
Free cash flow
-$68.79M
Per share
Balance sheet
Liquidity
EPS
-$4.06
EPS diluted
-$4.06
Free cash flow per share
-$3.71
Book value per share
-$3.09
Revenue per share
$0
TBVPS
$1.55
Total assets
$28.82M
Total liabilities
$101.9M
Debt
$29.74M
Equity
-$73.08M
Working capital
-$15.14M
Debt to equity
-0.41
Current ratio
0.64
Quick ratio
0.35
Net debt/EBITDA
-0.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-192.5%
Return on equity
N/A
Return on invested capital
-2,702.8%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OTLK stock price
How has the Outlook Therapeutics stock price performed over time
Intraday
-5.68%
1 week
-6.09%
1 month
45.95%
1 year
-70.65%
YTD
14.29%
QTD
14.29%
Financial performance
How have Outlook Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$71.7M
Net income
-$75.37M
Gross margin
N/A
Net margin
N/A
OTLK's operating income is down by 35% YoY and by 17% QoQ
The net income has contracted by 28% YoY but it has grown by 20% from the previous quarter
Growth
What is Outlook Therapeutics's growth rate over time
Valuation
What is Outlook Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 49% from the previous quarter and by 14% YoY
Outlook Therapeutics's equity has increased by 13% QoQ
Efficiency
How efficient is Outlook Therapeutics business performance
OTLK's return on invested capital has dropped by 129% year-on-year but it is up by 46% since the previous quarter
The company's return on assets has shrunk by 58% YoY but it rose by 18% QoQ
Dividends
What is OTLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OTLK.
Financial health
How did Outlook Therapeutics financials performed over time
OTLK's total assets is 72% smaller than its total liabilities
OTLK's total liabilities has surged by 118% year-on-year but it is down by 22% since the previous quarter
The quick ratio has dropped by 53% since the previous quarter and by 30% year-on-year
OTLK's debt is 141% greater than its equity
OTLK's debt to equity has surged by 83% year-on-year but it is down by 5% since the previous quarter
OTLK's debt is down by 16% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.